Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Juvenile Scleroderma: Staying One Step Ahead of a Rare Disease
-
- 6 Highly Accessed Articles About SLE Highlight Treatments, Risk Factors
- FDA Grants Breakthrough Therapy Designations for Canakinumab to Treat Periodic Fever Syndromes
- FDA Grants Orphan Drug Status to Gene-Therapy Candidate for Localized Scleroderma
- Flixabi Biosimilar to Infliximab Gains Positive CHMP Opinion
- The Rising Tide of Autoimmunity: Highlights of the International Autoimmunity Summit Leonard H. Calabrese, DO
- Psoriatic Arthritis
- Certolizumab Pegol May Relieve RA Symptoms, Reduce Methotrexate Use
- Draft EMA Guidelines Suggest DAS28 May Not Be an Appropriate Measure in Early RA
-
- Epratuzumab Seen as Well-tolerated, Steroid-sparing Treatment for SLE patients
- High Rate of Drug Survival, Reduced Glucocorticoid Use Seen With TNFi for Patients With Psoriatic Arthritis
- Patients with gout may benefit from arhalofenate
- Furie Discusses Advances in SLE Treatment
- Immune System, Response to Vaccines May be Modulated by Sleep Activity
- Katz Discusses Autoimmune Diseases from a Multidisciplinary Perspective
- Speaker: Glucocorticoid-induced Osteoporosis Risks are Undetermined
- New Industry Body Launched to Promote Biosimilars in the United Kingdom
-
- Prime Therapeutics Encourages Regulators to Finalize Biosimilar Standards
- Survey: Patients With Pain Cannot Identify NSAIDs, Do Not Discuss Pain With Their Physicians